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Summary
Background: The national and international guidelines emphasize the importance of the effective treatment of arterial 
hypertension. Nevertheless, low levels of control are observed, as well as low attainment of the recommended goals, indicating 
that it is important to plan and implement better treatment strategies. 
Objective: To evaluate the efficacy of a based treatment algorithm with olmesartan medoxomil. 
Methods: This is an open, national, multicentric and prospective study of 144 patients with primary arterial hypertension, 
stages 1 and 2, naïve to treatment or after a 2-to-3 week washout period for those in whom treatment was ineffective. The 
use of olmesartan medoxomil was assessed in a treatment algorithm divided into 4 phases: (i) monotherapy (20 mg), (ii-iii) 
associated to à hydrochlorothiazide (20/12.5 mg and 40/25 mg) and (iv) addition of amlodipine besylate (40/25 mg + 5 mg). 
Results: At the end of the algorithm treatment, 86% of the study subjects attained the goal of BP < 130/85 mmHg. Maximum 
reductions in SBP and DBP were -44.4 mmHg and -20.0 mmHg, respectively. The rate of systolic responders (SBP ≥ 20 
mmHg) and of diastolic responders (DBP ≥ 10 mmHg) was 87.5% and 92.4%, respectively.
Conclusion: The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical 
practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and 
amlodipine was effective in the attainment of the recommended goals for stage 1 and 2 hypertensive individuals. (Arq Bras 
Cardiol 2008;91(3):168-176)
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Introduction
The national and international guidelines and consensus 
point out the need for the optimized treatment of essential 
hypertension (EH); however, low rates of control and 
attainment of the recommended goals are observed. This fact 
indicates that better treatment strategies must be planned and 
implemented1-3.
In general, the V Brazilian Guidelines of Arterial Hypertension 
(V DBHA) and the JNC 7 recommend that, for stage 1 
hypertension*, the pharmacological treatment must be initiated 
with monotherapy, which can be a escale-dose regimen, in 
case of failure in attaining the blood pressure (BP) goal; it also 
recommends the use of associations when the SBP is 20 mmHg 
and DBP is 10 mmHg, respectively, above the goal. For patients 
with stage 2** EH, the use of drug associations can be considered 
in the beginning of the treatment, although the monotherapy 
is also indicated in some cases2-5. The goal for stage 1 and 2 
EH with low and moderate cardiovascular risk is BP < 140/90 
mmHg; for those with high cardiovascular risk, the goal is BP < 
130/85 mmHg and for those with very high risk, the goal is BP 
< 130/80 mmHg. Patients with nephropathy and proteinuria 
> 1.0 g/L a BP < 120/75 mmHg is recommended. However, 
is possible, it is better to attain even lower BP levels (BP ≤ 
120/80 mmHg)1.
The continuous follow-up of the patient, providing 
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* Diastolic blood pressure (DBP) from 90 to 99 mmHg, and Sistolic blood pressure (SBP) from 140 to159 mmHg.
** (DBP) from 100 to 109 mmHg, and (SBP) from 160 to 179 mmHg.
Table 1 – Incl�sion and excl�sion criteria 
Incl�sion criteria
Age: 30 to 75 years
Male and female individuals of any ethnicity. Women must be post-
menopausal or surgically sterilized.
Negative pregnancy test for reproductive-age women at the start of the study 
Stage 1 and 2 EH (casual DBP ≥90  mmHg and <110 mmHg and casual SBP 
≥140  mmHg and <180 mmHg)::
- no treatment for at least two weeks 
- undergoing ineffective anti-hypertensive treatment, wash out period of 14 
to 21 days
Sign the Informed Consent Form.
No previous history of mental disability.
Excl�sion criteria 
If the study participation results in risk to the health and safety of the study 
subject..
Cardiovascular diseases:
- Hypertension stage 3 (BP≥180/110 mmHg) or secondary hypertension.
- Hypotension (SBP<100 mmHg) throughout the study;
- Myocardial infarction with or without surgical interventions in the previous 6 
months
- Congestive cardiac failure, pulmonary edema, valvular alterations or 
rheumatic cardiopathy 
- Cerebrovascular events during the previous 6 months;
- Clinically relevant disorders in formation or conduction of the cardiac impulse 
or other clinically significant arrhythmias.
Comorbidities
- Uncontrolled Diabetes mellitus (through assessment and clinical history 
and/or fasting glycemia levels > 160 mg/dl)
- Angioedema, renal function alterations, clinically significant liver, 
gastrointestinal, neurological , hematologic or cardiovascular diseases;
- Gout, symptomatic hyperuricemia 
- Hydroelectrolytic disorders;
- Severe and/or active autoimmune or endocrine diseases
- Neoplasic, psychiatric and infecto-contagious diseases.
Others
- Alcohol or medication abuse, illicit drug use 
- Concomitant use of medications that are not allowed by the protocol 
- Hypersensitivity to the components of any of the study medications 
- Pregnant or nursing women, women who wish to get pregnant or those who 
presented a positive urinary pregnancy test throughout the study. 
information and emphasizing the importance of controlling 
the BP is fundamental for the therapeutic success. It also allows 
the monitoring of the clinical conditions and the assessment 
of the need to increase the dose or add other types of anti-
hypertensive drugs. 
 Olmesartan medoxomil (OM) is the newest drug of the 
class of Angiotensin II (A-II) receptor (AT1 receptor) blockers 
(ARBs). In comparative studies, it showed higher anti-
hypertensive efficacy when compared to other drugs from the 
same class and similar to amlodipine6-10. It can be associated 
with a thiazide diuretic [in general, hydrochlorothiazide (HCT)] 
and/or a calcium channel blocker to potentiate its effect in 
patients that are non-responsive to the monotehrapy1,4,5.
Methods
Study design and population 
This was an open, national, multicentric and prospective 
study. The study population was defined by the inclusion 
criteria listed in Table 1. The inclusion and exclusion criteria 
were based on the IV Brazilian Guideline of Hypertension 
- IV DBHA (applicable at the time of the study planning), 
on the safety aspects of the medications and the guidelines 
established by the regulatory authorities and by the 
International Conference on Harmonization (ICH)/Good 
Practices in Clinical Research (GPC).
This study was carried out in 14 research centers in Brazil 
with competitive inclusion 2 months after the inclusion of the 
first study subject, started in August 2006.
Treatment protocol and follow-up procedures 
The study was carried out according to the ICH-GCP, 
Declaration of Helsinki and the Brazilian legislation, after being 
approved by the Committee of Ethics in Research (CEP) of 
each Institution, in addition to CONEP (the National Council 
of Ethics in Research) and ANVISA (the National Agency of 
Sanitary Vigilance).
After the sreening visit (SV), the patients that met all 
inclusion and none of the exclusion criteria were selected 
to participate in the study (Table 1). From visit 1 onward, 
the study subjects received the study medication, following 
a scale-dose regimen according to the defined treatment 
plan (Figure 1).
Treatment Plan
The study was based on a four-phase treatment approach, 
each one lasting 4 to 9 weeks (Figure 1A). The measurements 
of casual BP in the 4th, 8th and 9th weeks were the parameters 
for the changing of phase, determining the uptitration-dose 
regimen or not. If the study subject had BP≥ 140/90 mmHg, 
he/she was immediately assigned to the next phase (at any 
time); if the BP levels were ≥ 130/85 mmHg and/or < 
140/90 mmHg, the medication was maintained for four more 
weeks (totaling 8 weeks) and, if necessary, for one more week 
(totaling 9 weeks). The home blood pressure monitoring 
(HBPM) was performed only in the 9th week of treatment, so 
it could be used as retrospective comparison with the main 
efficacy parameter of casual BP < 130/85 mmHg. When the 
study subject did not attain this goal, he or she was assigned 
to the next phase (Figure 1B).
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Figure 1 - B���d �����m�n� ��g�����m w��� ��m������n m�d���m�� (A) �nd ������w-u� �����du��� (������) (B); S��BP- �����d d�������� ����d �����u��; S�SBP- �����d ��������� ����d 
pressure; EH- essenssial hypertension; Lab assess.- laboratory assessment; OM- olmesartan medoxomil; HCT- hydrochlorothiazide; AMLO- Amlodipine Besylate; HBPM- home 
����d �����u�� m�n�����ng; V- ������ VA- V���� A (������ HBPM)��
The objective of the HBPM in this study was to evaluate 
the percentage of individuals that presented the “white-coat 
effect”, even after 8 weeks of treatment. This information 
would not result in any alteration of conduct and would be 
used only for a posterior analysis, providing a perspective on 
its use in new clinical studies, as it has been confirmed that 
it has a better prognostic value when compared to the casual 
BP measurement at the office. Stergiou et al11 calculated 
the size of the sample necessary for a comparative study 
between medications, using different methods of BP 
measurement based on their reproducibility and with a 
significance level of 0.05. Comparing to the casual BP 
measurement at the office, the use of the HBPM can reduce 
the sample by 30%12.
A BP level < 130/85 mmHg was considered as sign of 
therapeutic efficacy and, upon reaching it, the study subject 
concluded the study. Those who did not reach the primary 
BP goal at the end of the algorithm treatment regimen were 
considered as therapeutic failures (Figure 1). 
Parameters of the study efficacy 
The parameter of the study efficacy was the casual 
measurement of the blood pressure (BP) of the study subject, 
through the mean of three BP measurements, in the seated 
position, at each follow-up visit, even after the HBPM. The 
measurement was always carried out in the morning, in the 
same arm (chosen as the one with the highest pressure at the 
screening visit) and using the same device (OMRON HEM-
705CP), according to the recommendations of the IV DBHA, 
applicable at the moment when the protocol was designed. 
The analysis of the parameter of efficacy allowed us to 
determine the percentage of BP goal attainment of BP < 
130/85 mmHg. This BP value encompasses most of the stage 1 
and 2 hypertensive patients defined by the current guidelines; 
thus, a large part of the patients with more stringent BP levels 
is contemplated, considering that patients with stage-2 arterial 
hypertension (approximately 50% of the sample) are already 
considered as moderate risk and some can be considered 
high risk if they have other associated risk factors (as exclusion 
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criteria, we considered only patients with uncontrolled diabetes 
mellitus, defined through clinical assessment and/or glycemia 
levels > 160 mg/dl), who, in the present study were evaluated 
through the clinical examination of the cardiovascular system, 
electrocardiogram and laboratory assessment. 
Additionally, the IV and V DBHA also suggest that, although 
the goals to be attained vary from individual to individual, 
whenever possible one must seek values that are lower than 
120/80 mmHg. This information is based on the results 
published by Lewington et al13, who demonstrated that the 
risk for the development to an encephalic vascular accident 
and myocardial acute infarction increases 2-fold when the BP 
increases from 115/75 mmHg to 135/85 mmHg.
The BP measurement [casual at the doctor’s office or 
through Home Blood Pressure Monitoring (HBPM)] and the 
response and control rates of DBP and SBP in relation to the 
initial measurement allowed the attainment of the secondary 
objectives of the study, of evaluating the influence of the time 
of use (4 or 8 weeks) and the safety of OM, OM/HCT and 
OM/HCT+AMLO. 
Statistics
The sample size was calculated considering an open study 
of 4 consecutive phases with different expected response 
proportions for each one, that is, for each phase of the 
algorithm-treatment, it is expected that the proportion of 
responses be increasingly higher, which makes it necessary to 
have 154 valid study subjects. The risk of a false-positive result 
was defined as 5% and of a false-negative result, 10%.
Results
Patient distribution and baseline characteristics
In total, 459 patients were selected; of these, 276 were 
not approved at the screening process, thus resulting in a 
sample of 183 study subjects that comprised the intent-to-
treat population (who received at least one dose of olmesartan 
medoxomil 20 mg). Thirty-nine study subjects were excluded: 
12 due to lack to treatment adherence or protocol violation; 
7 abandoned the study protocol; 4 did not meet the inclusion 
criteria; 2 presented some exclusion criteria throughout the 
study; 9 presented some adverse event or use of proscribed 
medication and 5 due to error in medication dispensation. The 
elected cohort was then comprised of 144 study subjects, who 
were followed successfully up to the end of the study.
The initial study data (collected at V1), such as the main 
demographic data, previous anti-hypertensive treatment, body 
mass index (BMI), SBP, DBP and HR, are shown in Table 2. 
These data contemplate the main demographic characteristics 
of the 183 study subjects included in the study. 
Efficacy
The BP mean at the start of the study for the intent-to-treat 
population (ITT=183 study subjects) was 158/97 mmHg, as 
shown in Table 2. The final BP of this group was not calculated, 
as it was not the population assessed for the analysis of efficacy. 
The BP mean at the start of the study of the subjects that 
comprised the elected cohort (n=144) was 158/97 mmHg 
and 125/78 mmHg at the end of the study.
The number of subjects assessed for each phase of the 
algorithm-treatment was, respectively, 144, 106, 73 and 
32 (Figure 2).
 With the use of olmesartan medoxomil 20 mg in monotherapy, 
26% of the study subjects reached the main BP goal of BP < 
130/85 mmHg. With the addition of HCT 12.5 mg, a further 
23% of the study subjects reached the BP goal, totaling 49% 
and with OM/HCT 40/25 mg, 74% reached the BP goal. At the 
end of the algorithm treatment, 86% of the study subjects, of a 
total of 144 assessed subjects, reached the goal of BP < 130/85 
mmHg (Figure 2). The decreases in SBP and DBP for each 
treatment phase were, respectively: -30.5 and -19.1mmHg; 
-34.8 and -21.6 mmHg; -27.1 and -15.5 mmHg and -28.6 and 
-15.3 mmHg. If we evaluate only the study subjects that attained 
the BP goal (n=124), the decreases in SBP and DBP for each 
treatment phase were, respectively: -30.5 and -19.1 mmHg; 
-34.8 and -21.6 mmHg; -34.2 and -9.8 mmHg and -44.4 and 
-20.0 mmHg (Figure 3).
Regarding the time of treatment, that is, the time assessment 
in the dose-response to the use of the medication during each 
phase that varied from 4 to 9 weeks, it was observed that 
60.4% (n=87) of the study subjects attained the recommended 
BP goal (BP<130/85 mmHg) after 4 weeks of treatment, 
whereas 18.1% (n=26) did so after 8 weeks and 7.6% (n=11) 
after 9 weeks of treatment. 
The number of study subjects in whom the HBPM would 
have prevented the algorithm-treatment was 80% (n=16) of the 
20 study subjects that carried out the 9th week of treatment with 
the same dose of medication. 
Among the 144 assessed study subjects, the rate of systolic 
responders (reduction in SBP ≥ 20 mmHg) was 87.5% with 
a mean reduction of -36 mmHg; regarding the diastolic 
responders (reduction in DBP ≥ 10 mmHg) it was 92.4%, 
with a mean reduction of –20 mmHg. As for the systolic 
and diastolic responders, (SBP ≥ 20 mmHg and DBP ≥ 10 
mmHg) it was 86.8% with reductions of -36 mmHg and -20 
mmHg, respectively.
For the study subjects that attained the recommended BP 
goal, and who, in the beginning of study presented stage-1 EH 
(n=56), the mean reductions in SBP and DBP observed for each 
phase of the algorithm-treatment were -28.8 and -17.6 mmHg; 
-31.1 and -17.6 mmHg; -31.0 and -17.4 mmHg and -30.8 and 
-14.7 mmHg, respectively.
Similarly, for the subjects that had been classified as stage-
2 EH, the mean reductions in SBP and DBP observed were: 
-35.7 and -23.6 mmHg; -37.8 and -22.7 mmHg; -38.8 and 
-21.4 mmHg and -44.5 and -21.5 mmHg (Figure 4). The goal 
attainment outcome for this population is shown in Figure 5. 
Safety
The general incidence of adverse events that appeared 
during treatment was 21.5% and the main ones were: 3.5% 
headaches; 1.4% anxiety; 1.4% lumbar pain; 1.4% dizziness 
(Table 3). No case of lower limb edema was reported, not even 
with the use of OM/HCT+AMLO 40/25+5 mg. 
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Figure 3 - ��������� �n BP ��� ��� ��ud�� �u�j���� ���� ������d ��� BP g��� 
of BP<130/85 mmHg, by phase of the based treatment algorithm (n=124); 
SBP- ��������� ����d �����u��; �BP- d�������� ����d �����u��; OM- ��m������n 
medoxomil; HCT- hydrochlorothiazide; AMLO- amlodipine besylate.
Table 3 – More co��on ad�erse e�ents occ�rring d�ring treat�ent
Ad�erse 
E�ent 
OM 20 �g
(n=144)
OM/HCT 
20/12.5 �g
(n=106)
OM/HCT 
40/25 �g
(n=73)
OM/
HCT+AMLO 
40/25+5 �g
(n=32)
Miscellaneous 17 (11.8%) 11 (10.4%) 10 (13.7%) 5 (15.6%)
Anxiety 4 (2.7%) 2 (1.9%) 0 (0.0%) 0 (0.0%)
Headache 1 (0.7%) 1 (0.9%) 0 (0.0%) 0(0.0%)
Lumbar pain 1 (0.7%) 1 (0.9%) 0 (0.0%) 0(0.0%)
Dizziness 0 (0.0%) 2 (1.9%) 0 (0.0%) 1 (3.1%)
Figure 2 - Proportion of the study subjects that reached BP goal of BP<130/85 
mmHg at each phase of the algorithm-treatment (n=144); Mean initial BP: 
158/97 mmHg; OM- olmesartan medoxomil; HCT- hydrochlorothiazide; AMLO- 
�m��d���n� ����������
AMLOTable 2 - De�ogra��ic data and baseline c�aracteristics o�� t�e �atients (ITT sa��le) (n=183)
Variable Val�e
Age in years
30 to 39 yrs (%) 13.7
40 to 49 yrs (%) 26.8
50 to 59 yrs (%) 35.5
60 to 69 yrs (%) 18.6
 ≥70 yrs (%)  5.5
Mean age (yrs) 52
Sex
Male (%) 47.0
Female (%) 53.0
Et�nicity
Caucasian (%) 59.6
Black (%) 19.1
Asian (%)  3.8
Other (%) 17.5
Pre�io�s anti-�y�ertensi�e treat�ent
Naïve patients (%) 53.6
Treated patients (%) 46.4
Monotherapy (%) 58.8
Combined therapy (%) 41.2
Main �edications
Hydrochlorothiazide (%) 19.6
Amlodipine besylate (%) 15.0
Captopril (%) 13.5
Enalapril maleate (%) 11.3
Atenolol (%)  8.3
BMI† (kg/�2) 28.71 ± 4.58*
SBP (��Hg) 157.91 ± 10.89*
DBP (��Hg) 96.84 ± 5.3*
HR (b��) 74.92 ± 11.38*
* V��u�� �����n��d �� m��n� ± S�; †BMI (B�d�� M��� Ind��) ����u����d 
with n=182; SBP: systolic blood pressure; DBP: diastolic blood pressure; 
HR: heart rate. Discussion
The low rates of control and the stringent goals for patients 
with EH and additional cardiovascular risk factors clearly 
indicate the need for effective strategies in BP control, as it is 
well known that the percentage of hypertensive, non-controlled 
patients in the United States is high, being around 64.9%14.
Although the design of the present study, when it was first 
designed, used the IV DBHA, we observed that it remained 
up-to-date, as it contemplates the requirements and 
recommendations of the most current guidelines, i.e., the V 
DBHA. The guidelines recommend, for stage-1 hypertension, 
initiating the pharmacological treatment with monotherapy, 
which can be uptitratesd in cases of failure in attaining the BP 
goal. For patients with stage-2 hypertension, the use of drug 
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Figure 4 - Decreases in BP of the study subjects that reached the BP goal of BP<130/85 mmHg, by phase of the based treatment algorithm and by stage of hypertension; SBP- 
systolic blood pressure; DBP- diastolic blood pressure; OM- olmesartan medoxomil; HCT- hydrochlorothiazide; AMLO- amlodipine besylate.
Figure 5 - Proportion of study subjects that reached the BP goal of BP<130/85 mmHg at each phase of the based treatment algorithm according to the classification of hypertension; 
Mean initial BP: 158/94 mmHg (stage 1) and Mean initial BP: 164/99 mmHg (stage 2); OM- olmesartan medoxomil; HCT- hydrochlorothiazide; AMLO- amlodipine besylate.
associations must be considered, when there is no response 
to the monotherapy. Regarding the BP goal of BP<130/85 
mmHg, used in the present study as an efficacy parameter, 
most of the assessed study subjects presented moderate or high 
cardiovascular risk; additionally, the presence of comorbidities, 
especially diabetes mellitus, was not considered an exclusion 
criteria, as long as the parameters defined in protocol were 
respected (Table 1). Therefore, with the BP goal established 
for hypertensive patients with high cardiovascular risk 
stratification (including those with diabetes mellitus), most of 
the study subjects were contemplated, in addition to favoring 
a better prognosis of arterial hypertension with lower rates of 
cardiovascular outcomes1,14.
With the objective of reproducing the clinical practice, a 
titration treatment was established and evaluated every four 
weeks, which is the necessary period for the observation of the 
full action of olmesartan medoxomil, in a Brazilian population 
originated from several Brazilian cities (Recife, Maceio, Belo 
Horizonte, Rio de Janeiro, Sao Paulo, Sao Jose do Rio Preto, 
Campinas, Curitiba, Florianopolis and Porto Alegre).
The rationale of the study used three anti-hypertensive 
medications from different therapeutic classes for the 
algorithm treatment: an ARB (angiotensin II receptor blocker), 
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in this case, olmesartan medoxomil, a thiazide diuretic, 
hydrochlorothiazide, and a calcium-channel blocker, the 
amlodipine besylate. Olmesartan blocks the AT1 receptors for 
longer periods and has a higher rate of fixation, resulting in 
higher anti-hypertensive efficacy in relation to other ARBs, as 
observed in several comparative clinical studies6-10. For patients 
that need the combined therapy to attain the BP goals, the 
most frequent association is a thiazide diuretic (in general, 
hydrochlorothiazide) and/or a calcium-channel blocker1.
Hydrochlorothiazide is known to activate the renin-
angiotensin-aldosterone system (RAAS), providing an effective 
combination with the angiotensin II-AT1 receptor blockers. It is 
a thiazide diuretic that acts on the mechanisms of electrolyte 
resorption in the renal tubules, directly increasing sodium and 
chloride excretion in approximately equivalent amounts15. 
Amlodipine besylate is a calcium-channel blocker from 
the subgroup of dihydropyridines. It acts by preventing 
the entrance of calcium in the vascular smooth muscle 
cells, which decreases the peripheral vascular resistance6. 
As the associations of anti-hypertensive drugs must follow 
a logical decision of not combining two medications with 
similar actions, the addition of amlodipine to the ARB+HCT 
association is very convenient to promote the control in a 
larger number of patients1,3,5. 
 As for the initial demographic characteristics of the 
present study, there was a higher percentage of hypertensive 
patients aged 50 to 59 years, with 35.5%, followed by 40 to 
49 years, with 26.8%. Of the total number of patients, 53% 
were females, 59.6% were Caucasians and 53.6% were naïve 
to treatment. 
Of those who had been previously treated and did not have 
controlled BP (< 140/90 mmHg), 58.8% used monotherapy 
and the most often employed medication was, in general, 
hydrochlorothiazide, in monotherapy as well as associated 
to other medication. 
At the beginning of the study, the mean casual SBP was 158 
mmHg and the mean casual DBP was 97 mmHg. The mean 
BMI of the study subjects was classified as overweight (24.9 
to 29.9 Kg/m2). According to the V DBHA, the excess body 
mass is a predisposing factor for hypertension and it can be 
responsible for 20% to 30% of the cases of EH1. 
According to Caro et al16, the choice of the initial agent 
for long-term adherence to the anti-hypertensive therapy is 
very important. The results of the present study suggest that 
the use of an ARB, such as olmesartan medoxomil, followed 
by the addition of a thiazide diuretic, if necessary, and a 
calcium-channel blocker, represents an effective and safe 
algorithm-treatment regimen for hypertension. Considering 
that 81 study subjects (56.2%) presented stage-2 EH, it was 
necessary to attain significant reductions in SBP and DBP 
for the BP goal to be attained. As the study subjects were 
discontinued from the study as soon as they attained a BP 
goal of BP < 130/85 mmHg, the reductions in BP could be 
even higher. The regimen with more than one medication 
was well tolerated from the beginning to the end, without 
any increase in adverse events observed with the addition of 
HCT or amlodipine. 
The absence of reports of lower-limb edema as an adverse 
event might be occurred due to the methodology of the 
study, which did not include a specific questionnaire for the 
reporting of this specific adverse event, but a general inquiry 
about possible alterations that occurred during treatment. 
Other factors that might have contributed to this fact were 
the short duration of the treatment and the small sample size 
submitted to the treatment with amlodipine. 
The use of an ARB as a first-line agent for the treatment of 
hypertension is a known and frequently employed approach, 
due to its efficacy and safety profile, in addition to its capacity 
to promote the protection of target-organs1.
In an algorithm study carried out by Neutel et al17, it 
was demonstrated that the algorithm-treatment, based 
on olmesartan medoxomil and the addition of HCT and 
amlodipine, although with somewhat different times and 
doses, 87.7% of the patients attained the BP goal of BP ≤ 
130/85 mmHg after 24 weeks of treatment, which was very 
similar to the outcome of the present study (86%).
Izzo et al18 evaluated patients with isolated systolic 
hypertension (stage 2) in a algorithm-treatment study with OM 
and addition of HCT (20 mg, 40 mg, 40/12.5 mg and 40/25 
mg), and they observed that 70.4% of the patients attained 
the BP goal of BP< 140/90 mmHg and 15.4%, the BP goal 
of BP < 120/80 mmHg, which shows that the results of the 
efficacy as well as those of safety obtained in the present 
study are compatible and consistent with the results of studies 
published in American literature. 
The monotherapy with Olmesartan medoxomil 20 mg 
showed to be effective, as 26% of the study subjects attained 
the BP goal. Oparil et al9,10 observed that after 8 weeks of 
treatment with the same dose, 12.5% of the assessed patients 
attained the same BP goal; in both cases, the evaluation 
occurred in stage-1 and 2 EH patients.
The data of 8 weeks of treatment with the same dose, in 
case of patients that presented a BP level at a range considered 
to be borderline, i.e., < 140/90 mmHg, but not within the 
normal range (< 130/85 mmHg), made it possible to evaluate 
the influence of time on medication response. Therefore, it 
was observed that in 25.7% of the study subjects, the increase 
in the dose would be unnecessary.
The study of the 9th week of treatment (study subjects 
who, after prolonged use of the same dose, 8 weeks of 
treatment, maintained BP levels that were “borderline” for 
the control i.e., <140/90 mmHg, but above the study goal 
of 130/85 mmHg), can determine the number of subjects in 
whom the HBPM would have prevented the uptitration or 
the association with another medication, that is, making it 
possible to demonstrate by HBPM that the BP was within the 
goal ranges in a percentage of these study subjects, evaluating 
the influence of the “white coat effect” on BP control. We 
observed that, in this situation, the HBPM would prevent the 
titration in 80% of the cases, demonstrating its importance 
in the follow-up of patients with EH (considering the normal 
values of HBPM BP<135/85 mmHg).
The BP reductions obtained in the present study for the 
study subjects that had stage-1 and 2 EH in the beginning 
of the study, were on average, a little higher than those 
obtained by Neutel et al19. Furthermore, it was observed that 
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the study subjects that had stage-2 EH needed an association 
of medications to attain the BP goal (Figure 4 e 5). Thus, as 
recommended by the V DBHA, to initiate the treatment 
with a combination of drugs can help the patients attain the 
recommended BP goal. 
The present study was designed based on the physician’s 
clinical practices when giving treatment directions and thus, 
there was no need to perform a randomized, double-blind 
study with placebo. The main parameter of efficacy, the 
casual BP measurement, was obtained according to strict 
criteria and methodology, as it was necessary to follow 
the recommendations of the V DBHA to measure BP, use 
a standard digital BP measurement device and consider 
the mean of three measurements recorded to proceed 
with the decision-making regarding the next step, i.e., 
goal attainment, uptitration or dose maintenance for a 
complementary period for four more weeks. Hence, all 
efforts were made in order to avoid a bias regarding the 
study subjects as well as the physicians, which reflects the 
data accuracy. 
Conclusion
The assessments performed every four weeks and the 
use of medications from different therapeutic classes with 
an algorithm treatment showed that the treatment regimen 
proposed by the study can be a feasible and an effective 
therapeutic option.
The treatment with olmesartan medoxomil in monotherapy 
and associations showed to be very effective and safe. In 
patients with stage 1 and 2 hypertension (mean of 158/97 
mmHg), 86% of the individuals reached the goal of BP < 
130/85 mmHg. Additionally, there were significant decreases 
of up to 44 mmHg in SBP and up to 22 mmHg in DBP without 
a significant increase in adverse events. These data suggest 
that this approach is an effective option for the treatment 
for hypertension. 
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